Introduction
============

Autophagy is an essential process by which cytoplasmic molecules (proteins, lipids, nucleic acids, and polysaccharides) ([@B39]; [@B181]) and subcellular organelles such as mitochondria (mitophagy) ([@B38]; [@B74]) are delivered to the lysosome for degradation and recycling. It is an evolutionarily conserved pathway occurring in eukaryotic cells. It is induced under stress conditions such as absence of growth factors, low oxygen levels, or nutrient starvation ([@B88]; [@B188]; [@B192]; [@B105]) assuring cell survival. It is also required for development, differentiation, homeostasis and, in specific conditions, cell death ([@B89]; [@B102]; [@B198]). The three forms of autophagy are: macroautophagy -- the main pathway designated autophagy, microautophagy, and chaperone-mediated autophagy (CMA; [@B60]; [@B198]). In autophagy cytosolic double-membrane structures -- autophagosomes -- are formed. They sequester protein aggregates, damaged organelles, and microbes ([@B129]), moving along microtubules toward microtubule-organizing center ([@B62]), subsequently fusing with the lysosome to form autolysosomes where degradation and recycling by acidic lysosomal hydrolases takes place ([@B188]; [@B133]).

The main autophagy signaling is regulated by the mTOR pathway, essential for cell growth and protein synthesis among many other cellular pathways ([@B54]). There are two mTOR complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) ([@B54]). The mechanism(s) via which mTORC1 regulates autophagy are (is) currently unclear ([@B176]). In response to growth factors signaling (insulin in particular) and to elevated nutrient levels, conditions which inhibit AMP-dependent kinase (AMPK; [@B108]; [@B24]) mTOR suppresses autophagy. The most known pathway of upregulating autophagy is via the lipophilic antibiotic rapamycin, inactivating mTOR. Down-regulation of mTOR through rapamycin prevented mitochondrial-dependent apoptosis and resulted in the activation of autophagy ([@B139]; [@B36]; [@B122]). Pre-treatment with rapamycin has been shown to protect cell lines from pro-apoptotic insults in an autophagy-dependent way ([@B137]). These protective effects suggest that autophagy may protect from cell death ([@B192]). However, rapamycin treatment does not affect autophagosome dynamics (movement), so clearance by autophagy induction is likely because of the increase in autophagosome formation ([@B62]). Others autophagy mediators include the autophagy-related genes (ATG), conserved from yeast to mammals, and the microtubule-associated protein 1A/1B-light chain 3 (LC3), a protein family comprised of LC3, LC3A, and LC3B. During autophagosomes engulfment LC3 is cleaved to LC3-I and converted by phosphatidylethanolamine to LC3-II. The latter is recruited to autophagosomal membranes ([@B171]). LC3-II, a mammalian homolog of Atg8, is the best known autophagosome-specific protein marker ([@B115]) presented inside and outside of the autophagosomes. Its amount correlates with the size of the autophagosomes ([@B68]). p62/sequestosome 1 is a protein complex that when binding with LC3-interacting region (LIR; [@B95]) can localize to autophagic compartments transporting ubiquitinated proteins for degradation. This process is important for autophagic vacuoles (AVs) containing specific cargo ([@B76]). The protein Beclin1 is another regulator (the mammalian ortholog of the yeast Atg6/Vps30 gene). It interacts with B-cell lymphoma 2 (Bcl-2)-like proteins to form a complex. The complex is a key regulator of autophagy. Namely, its modulation either stimulates or inhibits this cellular pathway ([@B21]; [@B57]). In microautophagy cytoplasmic content is delivered into the lysosome by invagination of the lysosomal membrane into its lumen. Overall, the molecular mechanism of microautophagy regulation is still unclear ([@B60]). In the CMA pathway, activated during cellular hypoxic and ischemic stress, chaperones selectively transfer cytosolic protein aggregates into the lysosome for degradation. This occurs without vesicle formation ([@B32]; [@B198]).

Autophagy dysfunction has previously been associated with a variety of diseases such as cancer ([@B53]), muscular disorders (Danon's disease) ([@B123]), pathogen infections (Listeria monocytogenes) ([@B163]), cerebral ischemia ([@B190]), neurodegeneration ([@B197]; [@B133]; [@B190]), psychiatric disorders ([@B70]; [@B67]; [@B210]), and more. This review will focus on autophagy and its dual role -- in cell survival and in cell death in the central nervous system (CNS), namely, in neurodegenerative \[Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD) ([@B198])\] and psychiatric \[schizophrenia ([@B210]), bipolar disorder (BPD) ([@B126]), and unipolar depression ([@B67])\].

Post-mortem brain studies which found accumulation of autophagosome-like vesicles in axonal terminals of dysfunctional or degenerating neurons ([@B211]) in neurodegenerative disease patients ([@B203]), deviated expression of autophagy-related proteins in schizophrenia patients ([@B112]) along with studies indicating that autophagy enhancers induce an anti-depressant-like effect ([@B27]; [@B70]; [@B67]) implicate the involvement of aberrant autophagy in the pathogenesis of these disorders and suggest that enhancing the process protects against them ([@B89]).

Autophagy and Neurodegenerative Disorders
=========================================

Autophagy in the CNS is constitutively active ([@B79]), maintaining an important housekeeping role by eliminating defective proteins and organelles, preventing the accumulation of aggregates, providing energy demands, and supporting neuronal plasticity ([@B188]; [@B40]; [@B80]). Evidence indicates that autophagy plays a neuroprotective role ([@B133]). This role is particularly important in post-mitotic cells including neurons in order to protect against neurodegeneration and to promote cell survival ([@B89]; [@B122]). The neuronal soma exhibits basal levels of autophagy, mitophagy, and CMA, maintaining cellular homeostasis. Axon injuries induce accumulation of autophagosomes or AVs and dystrophic axonal swellings. Synapses require high energy and protein turnover. Therefore they are more vulnerable to autophagy dysfunction ([@B165]).

On the other hand, autophagy has been associated with promotion of cell death (type-II cell death) as a result of circumstances such as excessive activation of autophagy \[e.g., overexpression of the Atg1 in Drosophila ([@B158]), requirement for massive cell elimination and neuronal excitotoxicity ([@B26]; [@B79]; [@B48])\]. It is possible that excessive up-regulation of autophagy and long-term autophagy up-regulation eventually result in self-digestion or have harmful effects ([@B102]; [@B140]; [@B133]). The role of autophagy in cell death and the detailed mechanism are still unclear and it is under debate whether type-II cell death is apoptosis-related or is a separate process ([@B82]; [@B89]; [@B132]). Interestingly, apoptosis and autophagy share regulators such as Beclin1, Bcl-2, p53, and Atg5 which may interact to promote neuronal cell death ([@B200]; [@B116]). Beclin1 has been linked to protection against neurodegenerative diseases and to lifespan extension ([@B57]).

Protein aggregates are a result of defective protein production that can be caused by oxidative stress, ultraviolet radiation, toxic compounds, genetic mutations, post-translational modifications and more ([@B100]). The soluble forms are targeted for degradation via the CMA or the ubiquitin-proteasome pathways (UPS). The insoluble forms of the proteins form complex structures (oligomers and fibrils) making it difficult to traverse through the proteasome's pore ([@B182]) or to be degraded by the CMA pathway ([@B89]). In these instances autophagy is activated ([@B145]). However, when autophagy and other protein degradation systems are impaired/altered, neurons display accumulation of defective or mutant protein aggregates ([@B142]) leading to a toxic effect of cellular damage and ultimately to cell death associated with neurodegeneration ([@B56]; [@B79]; [@B89]; [@B122]). Indeed, blockade of autophagy in Atg5- and Atg7-deficient mice lead to the appearance of inclusion bodies accumulated in the cerebral cortex and the cerebellum, neurodegeneration and loss of neurons ([@B56]; [@B79]).

Presence of excessive accumulation of autophagy vesicles (autophagosomes and lysosomes) has been observed in post-mortem brain of patients with AD, PD and HD ([@B145], [@B146]; [@B192]) raising the question whether the accumulation of these vesicles is a result of autophagy dysfunction ([@B103]; [@B146]) or due to excessive autophagy ([@B163]).

Alzheimer's Disease
-------------------

Alzheimer's disease, the most common neurodegenerative disorder ([@B3]; [@B96]), is defined by memory loss and a decline in cognitive functions ([@B174]). It is characterized by progressive loss of neurons due to two pathologic lesions: (i) senile plaques consisting of extracellular β-amyloid (Aβ) deposit scattered among axons and dendrites. The plaques are derived from amyloid-precursor protein (APP) proteolysis ([@B207]; [@B102]) with an unclear biological function ([@B124]); (ii) neurofibrillary tangles composed mainly of tau-proteins that are abnormally phosphorylated and aggregated into filaments inside the neurons ([@B124]).

As recently reviewed ([@B93]; [@B117]) dysfunctional autophagy is implied in AD's pathogenesis. Evidence shows impaired maturation or fusion of autophagosomes with lysosomes or their transport toward the neuronal cell body. Endosomal--lysosomal dysfunction has also been presented as accumulation of AVs containing Aβ within dystrophic neurons and dendrites (neurites) in post-mortem human brain and in a mouse model of AD ([@B125]; [@B207]). It is unclear whether this reflects defective AVs clearance due to impaired autophagosomes-lysosomal fusion or due to enhanced autophagy ([@B145]). Inhibition of dynein function in PC12 cells \[dyneins are microtubule-based motor proteins responsible for the movement of cargo from the distal ends of axons to the cell bodies of neurons ([@B49])\] impaired the process and slowed clearance of proteins proned to aggregate (e.g., A53T α-synuclein) ([@B136]). A study in mouse blastocysts has shown that a mutation in the presenilin-1 gene (PS1) caused lack of clearance by autophagy and might account, at least partly, for protein accumulation in AD. PS1 is required for lysosomal turnover of autophagic and endocytic protein substrates. PS1 deletion caused loss of autophagy function due to impaired autolysosome acidification and cathepsin activation \[cysteine cathepsins are proteases responsible for proteolytic degradation within the lysosome ([@B168])\] ([@B85]). Accordingly, enhancing lysosomal cathepsin activity in an AD mouse model reduced the accumulation of Aβ, ubiquitinated proteins and other autophagic substrates within autolysosomes-lysosomes, and decreased extracellular and total brain amyloid deposition ([@B205]). Overall, these studies present prominent lysosomal dysfunction in AD ([@B191]). In AD mice models autophagosome presence in dendrites increases before deposits are created, indicating autophagy as a primary response and not as an outcome of deposit formation ([@B124]). It is suggested to be a prior event of the abnormally accumulation of AV's. Furthermore, APP, PS1 and other substrates necessary for the generation of Aβ peptides were identified in isolated AVs of AD mice models livers ([@B208]), suggesting potential AVs' role in Aβ generation ([@B207]).

Long-term inhibition of mTOR by rapamycin administration (to increase autophagy) prevented AD-like cognitive deficits and lowered Aβ levels ([@B166]). A study in AD patients' mid-frontal cortex gray matter found reduction of beclin1 protein levels. Inducing haploinsufficiency of the beclin1 gene in mice decreased neuronal autophagy and led to neurodegeneration and lysosome disturbance. Moreover, in an AD mouse model, reduction of beclin1 expression resulted in increased intraneuronal and extracellular Aβ accumulation, substantial neuronal abnormalities and neurodegeneration ([@B131]). According to evidence presented above of gradually impaired autophagy seen as autophagic-lysosomal dysfunction and the loss of proteasome activity ([@B73]), neurons are left without a coping mechanism against toxic protein accumulation and there is a sense in restoring normal autophagy as a therapeutic strategy.

A vicious circle, in which neuronal mitochondrial dysfunction, apparently due to impaired mitophagy occurring early in the disease development and resulting in oxidative damage and cellular energy deficits which, in turn, further impair mitophagy has also been recently suggested to promote Aβ and Tau pathologies ([@B164]).

Huntington's Disease
--------------------

Huntington***'***s disease is an inherited autosomal dominant disease ([@B101]) characterized by insoluble aggregation of an abnormally long polyglutamine (also called inclusions) caused by a gain-of-function mutation in the huntingtin gene ([@B175]; [@B47]). This accumulation leads to progressive memory loss, cognitive decline, impaired movement and more ([@B101]). The mutation is expressed by expansion of cytosine--adenine--guanine (CAG) repeats at the N-terminus of the huntingtin gene. This condition contributes to slow progressive neuronal loss in the striatum and cortex that leads to death. The onset age is between 35 and 50 years and it is a progressive disease with clinical manifestations such as motor disturbances, cognitive decline, bradykinesia, rigidity, muscle wasting, weight loss, and eventually death ([@B47]). Diverse mechanisms such as apoptosis, oxidative stress and mitochondrial dysfunction have been implicated in HD pathophysiology ([@B47]). In addition, studies suggest that autophagy plays a central role in the progressive degeneration of HD ([@B102]). Indeed, observations in HD mouse models and in cells from humans with HD identified a specific autophagic defect in which the ability of AVs to recognize and trap cytosolic cargo is compromized ([@B104]).

Huntington's disease mouse models show that the ubiquitin-proteasome system tends to become overloaded with the increasing number of aggregates and this impairment activates cell death pathways through apoptosis or autophagy ([@B61]). Expression of mutated huntingtin causes endosomal-lysosomal activity ([@B72]) and HD brains display endosomal-lysosomal organelle accumulation ([@B173]; [@B150]). Also, it has been shown that the number of AVs in lymphoblasts of HD patients correlated with the length of the polyglutamine expansion ([@B119]).

Autophagy may be the cell's way to eliminate the huntingtin mutants. It has been reported that abolishing huntingtin mutant expression in mice models of HD prevents symptoms of progression and may reverse aggregate formation and progressive motor decline ([@B202]). Also, stimulation of autophagy in clonal striatal cells, PC12 cells and rodent embryonic cells promoted degradation of huntingtin whereas blocking autophagy reduced cell viability and increased the number of cells containing aggregates of mutant huntingtin ([@B134]). Over-expression of the transcription factor TFEB (transcription factor EB) in the striatum of HD-mutant mice stimulated autophagy and lysosome activity and lowered mutant huntigtin levels ([@B183]). Another study supporting this observation has shown increased autophagy only in HD model cells expressing mutant aggregates and demonstrated that treatment with rapamycin or its analog CCI-779 in fly and mouse models reduced aggregate formation and cell death and presented improvements in phenotypes related to neurological dysfunction ([@B139]). Yet, rapamycin's mTOR activity inhibition might be impaired following long huntingtin expression or increased formation of its aggregates probably due to mTOR sequestration in inclusions resulting in lower levels of soluble mTOR ([@B138], [@B139]).

Studies have revealed that if the production of the aggregates is halted the cells have the ability to clear them. In a study that exemplifies this notion autophagy triggered clearance through the activation of beclin1 and Vps34 promoted by insulin receptor substrate 2, despite activation of Akt and mTOR. This implies an mTOR-independent autophagy activation ([@B201]). However, accumulated mutant huntingtin recruits Beclin1 impairing its activity thereby reducing autophagic degradation. The mechanism of the latter process has recently been uncovered by [@B6]. They demonstrated that the activity of ataxin-3 (which interacts with beclin1 allowing its deubiquitinase activity to protect beclin1 from proteasome-mediated degradation enabling autophagy) mediated by its polyQ domain was competed by other soluble proteins with polyQ tracts in a length-dependent fashion. In cells expressing mutant huntingtin exon 1, in brain of HD mouse model and in HD patient cells this resulted in impaired starvation-induced autophagy. They also observed decreased beclin1 levels and impaired starvation-induced autophagy in fibroblasts derived from HD patients, compared to controls. Furthermore, in human brains beclin1's expression declines with age which may result in parallel reduction in autophagic activity ([@B162]).

Parkinson's Disease
-------------------

Parkinson***'***s disease is characterized by tremors, muscular rigidity, and bradykinesia caused by progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) followed by accumulation of mutant protein inclusions in Lewy bodies ([@B45]). Interestingly, mutations in different subtypes of PD can affect different stages of autophagy ([@B71]). In familial PD accumulation of mutant α-synuclein (A53T and A30P) in the Lewy bodies is implicated in the disease pathogenesis ([@B34]; [@B28]). Wild-type α-synuclein, a protein of unknown function, is implied as a pre-synaptic regulator of dopamine neurotransmission ([@B1]) and is normally translocated into lysosomes for CMA degradation ([@B189]; [@B28]). The pathogenic α-synuclein mutants bind to the lamp2a receptor located on the lysosomal membrane acting as uptake blockers thereby inhibiting their own and other substrates' degradation, resulting in an up regulation of autophagy as a compensatory response ([@B102]). It has been shown that autophagy plays a role in the degradation of the α-synuclein mutants ([@B189]). Accordingly, lysosome-like vacuoles were observed in the dopaminergic neurons of the SNpc of PD patients ([@B5]; [@B216]). Inhibition of autophagy by α-synuclein over-expression has been shown to result in mislocalization of the autophagy protein Atg9 and to decrease autophagosome precursors formation ([@B195]).

Another mutated gene that has been linked to PD is the loss-of-function Park2, coding for the ubiquitin-ligase parkin. In mammalian cells parkin is recruited to dysfunctional mitochondria exhibiting low membrane potential mediating the engulfment of mitochondria by autophagosomes. Mutations in this gene result in failure to eliminate dysfunctional mitochondria, implying autophagic and mitochondrial dysfunction in the pathogenesis of PD ([@B120]). In a recent review Beilina and Cookson ([@B11]) discuss the relationships between protein products of PD genes and indicate their links with regulation of the autophagy--lysosome system attesting that such an interaction only exists for some of the genes. Similarly, [@B14] propose that the ATP13A2 gene (mutated in some types of early-onset Parkinsonism) and the SYT11 gene (associated with PD, the transcription of which is regulated by ATP13A2) comprize a regulation network of the autophagy--lysosome pathway. To sum-up, the autophagy--lysosome pathway in PD might be the neurons' attempt to compensate dysfunctional degradation pathways that backfire, causing further damage to the cell, eventually leading toward cell death, thus contributing to PD-associated neurodegeneration. However, perplexing data have recently been described. Based on the report that microRNA (miR)-181a is downregulated in PD ([@B31]), [@B97] overexpressed miR-181a in MPP-treated human neuroblastoma cells (an accepted PD-like model). It resulted in a significant decrease of the expression of the autophagy markers LC3II/LC3I ratio and Beclin1, but also in attenuated cell apoptosis.

Autophagy and Psychiatric Disorders
===================================

Schizophrenia
-------------

Schizophrenia is a mental disorder with a prevalence of 1% in the population characterized by positive (e.g., disturbed thoughts and perception, delusions, and hallucinations) and negative (e.g., diminished emotional expression and motivation) symptoms, disorganized thinking, cognitive and emotional decline, severe reduction in social functioning and hampered coping abilities ([@B128]; [@B141]; [@B170]; [@B210]). The onset mostly occurs at late adolescence ([@B128]; [@B141]). The etiology is unknown, but it appears to have developmental changes at synapses among other sites ([@B128]; [@B9]). Autophagy is suggested to have a key role in the pathophysiology of schizophrenia ([@B112], [@B110]; [@B210]). Beclin1 mRNA levels were reported to be 40% reduced in post-mortem hippocampal samples of schizophrenia patients compared to control subjects ([@B110]). Similarly, reduced Beclin1 mRNA and protein levels and decreased LC3-II levels were found in the hippocampus of schizophrenia mouse models ([@B112]; [@B210]).

Schizophrenia, originally named "dementia praecox" and AD share similarities and it is suggested that neurodegeneration also plays a role in the pathophysiology of schizophrenia ([@B94]; [@B58]). Both disorders share gene expression changes in the superior temporal gyrus including downregulation of autophagy-related genes such as beclin1 and ATG3 ([@B58]). This may suggest that autophagy dysfunction is shared by both disorders, although their underlying neurobiology is different.

Activity-dependent neuroprotective protein (ADNP) is necessary for brain formation, development, neuroprotection, and plasticity. The protein directly interacts with LC3II, suggesting its role in autophagy ([@B10]; [@B110]). ADNP^+/−^mice exhibited cognitive dysfunction, increased tau hyper-phosphorylation and memory impairment, tangle-like structures and neurodegeneration reminiscent of AD ([@B184]). Our group has demonstrated that "disturbance of ADNP in schizophrenia has a negative effect on autophagic activity; ADNP and ADNP2 (homologous protein of ADNP) expression was deregulated in post-mortem hippocampus of schizophrenia patients compared to healthy matched controls and the deregulation correlated with the disease progression" ([@B33]; [@B110]). We argued that "increased ADNP and ADNP2 expression in lymphocytes from schizophrenia patients compared to healthy controls and a negative correlation with disease duration may be a compensatory mechanism. Additionally, beclin1 mRNA levels was decreased by ∼20% in the ADNP^+/−^ mouse hippocampus, coupled to ∼30% increase in Bcl2, suggesting an impact of ADNP deregulation on brain autophagy" ([@B110]). Interestingly, administration of the peptide sequence NAP (NAPVSIPQ), derived from ADNP, inhibited apoptosis ([@B86]; [@B52]), enhanced ADNP-LC3-II interaction ([@B112]), reversed the decrease in hippocampal Beclin1 mRNA levels in a mouse model of schizophrenia (MAP6-deficiency) and decreased cognitive deficits and tau hyperphosphorylation in ADNP^+/−^mice ([@B184]). NAP also decreased schizophrenia-like hyperactivity in a different mouse model of schizophrenia ([@B111]). Phencyclidine (PCP), a non-competitive antagonist of glutamatergic *N*-methyl-[D]{.smallcaps}-aspartate receptor, induces positive- and negative-like signs exhibited by schizophrenia patients ([@B63]).

Recently, [@B66] used the PCP-induced schizophrenia-like behavior in perinatal rats and reported alterations in autophagy markers.

Another indication for the possible involvement of aberrant autophagy in schizophrenia relates to the apolipoprotein L1 (ApoL1) gene. Overexpression of ApoL1 induces autophagic cell death ([@B215]) and expression of ApoL1 was found to be significantly upregulated in post-mortem brain of schizophrenia patients ([@B114]). Moreover, in humans, the ApoL1 gene is localized to chromosome 22q13.1, a region with loci suggested to be linked to susceptibility to schizophrenia ([@B169]). Observation of reduced Beclin1 in post-mortem brains of schizophrenia patients and mouse models could indicate autophagy's link to the pathogenesis of the illness.

Bipolar Disorder
----------------

Bipolar disorders ([@B12]) are a group of mental disorders with high heritability ([@B106]; [@B75]) and estimated life-time risk of 1--2% in the adult population. BPDs are characterized by mood swings between depression and mania ([@B99]) resulting in hampered functioning, impaired cognition and disrupted life of the patients and their families ([@B212]. The manic phase is defined by a "hyper" state, enhanced motor activity, improper judgment, racing thoughts and decreased sleep. The depressive phase is defined by major depression symptoms, such as depressed mood, cognitive changes, psychomotor changes, and more ([@B50]; [@B51]). The etiology/pathophysiology of the illnesses is still unknown but accumulating data point at brain mitochondrial dysfunction as a central characteristic of BPDs ([@B157]). [@B178] suggested that disturbed mitochondrial function in BPD is a result of impaired autophagy.

Searching for studies linking autophagy with BPD yielded very few indirect results, dealing, mostly, with mood stabilizers, and autophagy (see section "The potential of autophagy-related therapeutic strategies for the treatment of neurodegenerative and psychiatric disorders").

Major Depression Disorder
-------------------------

Major depressive disorder (MDD) is a mental illness characterized by depressed mood, decreased interest or pleasure in most activities, low energy or fatigue, sleep disturbances and more ([@B13]; [@B37]; [@B4]). This condition has an overall lifetime prevalence of up to 17% ([@B84]) with a significant effect on the quality of life, high rates of morbidity and mortality and an enormous economic burden on the society ([@B187]). The pathogenesis of MDD is yet unknown although some hypotheses such as dysfunction of synaptic plasticity ([@B185]; [@B83]), increased apoptosis ([@B161]; [@B113]) and aberrant autophagy ([@B43]; [@B67]) prevail.

Some studies have implicated deficits in the mTOR signaling system in MDD. mTOR protein levels were reported to be reduced in post-mortem prefrontal cortex of MDD patients ([@B65]). Chronic stress is frequently used to model MDD in rodents. In the amygdala of rats exposed to chronic stress reduced phosphorylation of components of the mTOR signaling pathway was observed ([@B23]).

[Figure 1](#F1){ref-type="fig"} summarizes the autophagy pathway and its components reported to be deviated in neuro-psychiatric disorders.

![Components of the autophagy pathway reported to be deviated in neuropsychiatric disorders. AD, Alzheimer's disease; AKT/PKB, RAC-alpha serine/threonine-protein kinase/protein kinase B; ATG, autophagy-related genes; Bag, Bcl-2 associated athanogenes; Bcl-2, B-cell lymphoma 2; BP, bipolar disorder; CP, ceruloplasmin; GF, growth factor; HD, Huntington's disease; Hip, Hsp70-interacting protein; Hop, Hsp70-Hsp90 organizing protein; HSP, heat shock protein; IP~3~, inositol 1,4,5-trisphosphate; Lamp2a, lysosome-associated membrane protein-2; LC3, light chain 3; MDD, major depressive disorder; mTOR, mammalian target of rapamycin; PD, Parkinson's disease; PE, phosphatidylethanolamine; SCZ, Schizophrenia.](fncel-13-00196-g001){#F1}

The Potential of Autophagy-Related Therapeutic Strategies for the Treatment of Neurodegenerative and Psychiatric Disorders
==========================================================================================================================

As summarized above both neurodegenerative diseases and psychiatric disorders exhibit characteristics of aberrant autophagy which might be a central pathophysiological factor. Therefore, we contend that modifying autophagy pharmacologically might be an approach to prevent or to halt neurodegenerative and psychiatric disorders by potentially enhancing the removal of aggregated mutant proteins/dysfunctional mitochondria by their degradation, thus protecting from cell death/distrees. Evolving conceptualization supported by molecular, cellular and behavioral data suggests that affective disorders might be regarded as neurodegenerative ones involving plasticity- and resilience-related cascades ([@B8]; [@B35]; [@B135]; [@B19]). In this respect, one study suggested that protein aggregation is a common feature of neurodegenerative diseases ([@B172]) while another one -- that beyond neurodegenerative disorders protein aggregation might also be involved in affective disorders ([@B87]). The latter reported an increase in protein aggregates in post-mortem brains of affective disorders (MDD and BPDs) and schizophrenia patients as compared to controls.

The mTOR-dependent autophagy enhancers metformin, resveratrol, isorhynchophylline and rapamycin have all been shown to increase α-synucleine clearance and reduce cell death in various PD and AD models ([@B127]; [@B199]; [@B98]; [@B121]; [@B81]). Mitochondrial pyruvate carrier (MPC) is a key controller of cellular metabolism that influences mTOR activation and has recently been reported to regulate autophagy. A compound that specifically targets MPC, to reduce its activity exhibited neuroprotective and anti-inflammatory effects in several PD models ([@B46]).

The mTOR-independent *autophagy enhancers include: a. Trehalose*, a disaccharide present in many non-mammalian species, induces autophagy and has been shown to enhance the clearance of mutant huntingtin and α-synuclein mutants in mammalian cell cultures such as monkey kidney and human neuroblastoma cells ([@B151]). Studies toward unraveling the mechanism by which trehalose regulates autophagy revealed the involvement of autophago-lysosomal components including TFEB ([@B160]) as well as transient enlargement and permeabilization of the lysosomes. Furthermore, trehalose treatment led to transcriptional activation of autophagy-related TFEB targets ([@B147]). The latter corroborates our group's report that trehalose administration to mice resulted in reduction of frontal cortex p62/beclin1 ratio suggesting enhancement of autophagy ([@B70]). *b. Ca^2+^ channel antagonists, calpains, cyclic AMP (cAMP) and Gi signaling activators* induce autophagy in a variety of cells in an mTOR-independent pathway. For example, reduction of cAMP which regulates IP~3~ levels lead to a cascade of signaling with numerous potential points where autophagy can be induced ([@B193]). c. Three *small-molecule enhancers (SMER) and inhibitors (SMIR)* were identified with the ability to enhance autophagy clearance of mutant huntingtin and A53T α-synuclein in yeast independently of rapamycin ([@B152]). Antidepressants and mood stabilizers have also been reported to affect autophagy. *Lithium*, the prototype mood stabilizing drug commonly used in the treatment of bipolar patients, affects neurons at an array of parameters including neuronal growth factors, inhibition of oxidative stress and autophagy ([@B20]), resulting, in animal models, in neuroprotection -- potentially beneficial against neurodegeneration ([@B156]; [@B16]). It has been shown ([@B194]; [@B153]) and confirmed ([@B148]) that lithium is an autophagy enhancer via inositol metabolism in several mammalian cell lines and in mouse brain. In this context lithium has also been shown to reduce neurodegeneration in Drosophila models of HD ([@B154]). The beneficial effect was shown to be achieved by enhancing autophagic activity through inhibition of inositol monophosphatase and inositol transporters, free inositol depletion and decreasing inositol 1,4,5-trisphosphate (IP~3~) levels ([@B130]; [@B153]; [@B155]). It resulted in enhanced clearance of autophagy substrates like mutant huntingtin and a-synucleins ([@B153], [@B154]). However, opposite responses of autophagy to lithium were also observed. Lithium administration to neonatal rats with hypoxia-ischemia (HI) brain injury inhibited autophagy, as reflected by lowered levels of immuno-stained LC3 accompanied by neuroprotection. In contrast, increased LC3 levels were observed in rats with HI without lithium treatment ([@B92]). It is unclear whether a direct lithium's neuroprotective effect reduced the requirement for autophagy, or whether lithium directly downregulated autophagy. Attempts to elucidate whether enhanced autophagy following HI reflects a failed compensatory effect or the mechanism mediating cell death have been limited due to the lack of specificity of pharmacological inhibitors.

Lithium has also been shown to inhibit (*in vitro*) glycogen synthase kinase-3β (GSK-3β) that reduces autophagy by activating mTOR ([@B77]; [@B167]; [@B154]). However, we have recently shown that lithium's inhibition of GSK-3β does not occur in lithium-treated patients ([@B7]). Additional mood stabilizers proven to cause inositol depletion ([@B194]), *valproic acid and carbamazepine*, were also reported to upregulate autophagy ([@B42]; [@B140]), reduce apoptosis and alleviate mitochondrial dysfunction in rotenone-exposed SH-SY5Y cells, a PD model ([@B193]; [@B59]).

*Ketamine*, a recently recognized rapid-acting antidepressant ([@B15]; [@B213]; [@B30]), has been shown to activate mTOR in rat prefrontal cortex resulting in increased synaptic signaling proteins and number and function of new spine synapses ([@B91]). A similar effect of a continued increase of mTOR phosphorylation from baseline up to 100 min following ketamine infusion was observed in peripheral blood cells of a depressed patient ([@B91]) and in the plasma of three patients ([@B29]; [@B204]). Activation of mTOR may be expected to inhibit autophagy rather than activate it. However, except from mTOR's role as an autophagy inhibitor, mTOR is influenced by the activity of neuronal receptors including *N*-methyl-[D]{.smallcaps}-aspartate (NMDA) and tyrosine kinase (Trk) B. Indeed, chronic ketamine administration had no effect on depressive-like behavior and frontal cortex autophagy in mice ([@B69]).

Conventional antidepressant drugs have also been shown to enhance autophagy via several molecular mechanisms \[[@B2] ([@B55] \#379)\]. *Amitriptyline* and *citalopram* upregulated the expression of the autophagy markers LC3B-II and Beclin1 in primary astrocytes and neurons ([@B217]). Beclin1 was increased following acute antidepressant treatment in mouse brain ([@B44]). In a mouse model of depression, learned helplessness (LH), treatment with *fluoxetine* resulted in elevation of Beclin1 expression and mitophagy protein levels ([@B90]). Exposure of glioma cells to *imipramine* inhibited PI3K/Akt/mTOR signaling, stimulated the conversion of LC3-I to LC3-II and re-distributed LC3 to autophagosomes, suggesting stimulation of autophagy progression ([@B64]).

An add-on double blind placebo-controlled pilot phase II study of AVN-211 (3-sulfonyl-pyrazolo\[1,5-a\]pyrimidine), a specific antagonist of the G-protein coupled receptor 5-HT6R, showed a pro-cognitive (attention) effect in patients with schizophrenia stabilized on antipsychotic medication ([@B118]). 5-HT6R activation increased mTOR signaling in rodent prefrontal cortex ([@B107]). Hence, these observations raise the possibility that recruitment of mTOR by prefrontal 5-HT6R plays a role in the ruffled cognition in schizophrenia and offers a novel target for its therapy.

Discussion
==========

Autophagy plays a key role in maintaining cellular homeostasis and survival by promoting a clearance mechanism of mutant/misfolded proteins. Despite a dramatic progress in understanding the molecular and cellular mechanisms of autophagy in the past two decades full comprehension is still limited. Reviewed here is evidence of autophagy's important role in neurodegenerative and mental illnesses. However, it is still unclear under which circumstances enhanced autophagy plays a role in cell death or represents a rescue mechanism with protective effects ([@B145]; [@B22]; [@B78]). Furthermore, whether autophagy can cause cell death directly or is it a secondary effect of apoptosis remains an open question ([@B163]). Some studies have shown that inhibition of autophagy increases neuronal survival in cases such as hypoxic/ischemic brain injury in mice and necrotic cell death in *Caenorhabditis elegans* ([@B206]; [@B25]; [@B78]; [@B149]; [@B180]). It should be noted though that the increased number of autophagosomes is not always an indicator of enhanced autophagy. It may also be translated as either accumulation of uncleared autophagosomes due to impaired fusion to the lysosomes, or as a dysfunction in one of the various autophagy induction pathways ([@B17]; [@B144]).

Autophagic failure consequences are different depending on the stage at which failure occurs. It might occur at the level of autophagosome formation, resulting in accumulation of discarded cargo such as misfolded proteins and/or dysfunctional mitochondria leading to a toxic cost to the neuron ([@B56]; [@B79], [@B80]). Another failure level might be the recognition of autophagic cargo. This may cause the same corollaries as above, and depends on the extent of the recognition of dysfunction and the type of cargo. A third level of defect might arise if the autophagosomes are not cleared properly, leading to their accumulation. This might interfere with intracellular trafficking and even result in toxic outcomes as seen in AD, where the presence of APP in autophagosomes results in the production of β-amyloids ([@B207]). Hence, as summarized by [@B214] both ubiquitin proteasomal system (UPS) dysfunction and the autophagy-lysosomal pathway (ALP) impairment might be involved in the pathological misfolded/aggregated protein clearance. Identifying the specific level of autophagy failure is imperative for future development of therapeutic modalities.

In relation to potential therapeutic strategies for the treatment of neuropsychiatric disorders based on the intervention in autophagy lithium provides a crossroad linking autophagy, mood stabilization (an anti-depressant and an anti-manic agent) and, possibly, neurodegenerative/neurodevelopmental disorders. Lithium has been shown to enhance autophagy and to upregulate mitochondrial function, both effects mediated by inositol depletion ([@B153]). Enhanced autophagy may result in enhanced clearance of damaged mitochondria (mitophagy) resulting in increased mitochondrial turnover and, consequently, in upregulated mitochondrial function. Indeed, a transcriptomics study of our group found "up-regulation of mitochondrial genes in lithium treated mice and in phosphoinositide cycle-related knockout mice" ([@B177]; [@B179]) corroborating reports regarding mitochondrial dysfunction in bipolar patients ([@B186]). Hence, lithium might be considered as a treatment strategy to enhance autophagy in an mTOR-independent manner in neurodegenerative diseases such as HD ([@B153]). Another therapeutic option might have been rapamycin-induced mTOR inhibition. However, since mTOR inhibition affects other pathways ([@B137]), and since chronic rapamycin treatment is accompanied by severe side effects ([@B18]), more specific ways to activate autophagy are required. Furthermore, it has been shown that rapamycin loses its efficacy during the progression of HD ([@B139]). A different potential thinking path may be based on the finding that neuroinflammation affects brain autophagy and contributes to the progression of neurodegenerative disorders ([@B41]). This may imply a new therapeutic strategy for CNS disorders. An additional issue to be considered is genetic findings showing that proteins related to neurodegeneration, such as huntingtin, participate in autophagy as one of their physiological functions ([@B109]). This suggests that the applicability of targeting autophagy as a whole might be limited in neurodegenerative diseases ([@B159]). Hence, perhaps future efforts should focus on targeting specific types and steps of the autophagic process.

When considering intervention in autophagy as an approach to overcome neuropsychiatric disorders age might be a crucial factor to be considered. In adulthood-related disorders such as neurodegenerative diseases (and certain tumors) autophagy-inducing drugs have been shown to be beneficial ([@B89]; [@B196]; [@B143]). We have previously demonstrated antidepressive- and antimanic-like effect of autophagy enhancers in *adult* rodents ([@B70], [@B69]; [@B148]). Perplexingly, as mentioned above, HI in the *immature brain* resulted in *increased autophagy in injured neurons* ([@B92]). In addition the authors demonstrated that lithium protects neurons derived from postnatal day 8--9 of rodents by inhibiting apoptosis and autophagy. In this respect it is interesting to note that a recent clinical trial ([@B209]) found that low dose lithium (well established to enhance autophagy in cells in culture and adult brain) improved cognitive performance and adaptive behavior in children aged 4--11 years old with intellectual disability. As information regarding autophagy in oligodendrocytes in intellectual disability is still missing, it is imperative, both at the basic/translational and at the applicative level, to investigate whether there are age-related differences in the mechanism(s) of lithium-induced beneficial outcomes via the drug's effect on autophagy.

In conclusion, stimulation of autophagy in neuropsychiatric disorders may be a neuroprotective strategy, keeping in mind avoiding excessive process which might be destructive. It is essential to take into account that modifying autophagy may lead to diverse consequences and interfere with mechanisms yet unraveled. By revealing the molecular mechanisms involved in autophagy and the role of this process in neuronal life and death pathways it might be possible to either inhibit or stimulate autophagy for therapeutic purposes.
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